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Abstract
Single nucleotide polymorphisms (SNPs) on chromosome 9p21 are associated with coronary artery disease, diabetes, and
multiple cancers. Risk SNPs are mainly non-coding, suggesting that they influence expression and may act in cis.W e
examined the association between 56 SNPs in this region and peripheral blood expression of the three nearest genes
CDKN2A, CDKN2B, and ANRIL using total and allelic expression in two populations of healthy volunteers: 177 British
Caucasians and 310 mixed-ancestry South Africans. Total expression of the three genes was correlated (P,0.05), suggesting
that they are co-regulated. SNP associations mapped by allelic and total expression were similar (r=0.97, P=4.8610
299), but
the power to detect effects was greater for allelic expression. The proportion of expression variance attributable to cis-
acting effects was 8% for CDKN2A, 5% for CDKN2B, and 20% for ANRIL. SNP associations were similar in the two populations
(r=0.94, P=10
272). Multiple SNPs were independently associated with expression of each gene (P,0.05 after correction for
multiple testing), suggesting that several sites may modulate disease susceptibility. Individual SNPs correlated with changes
in expression up to 1.4-fold for CDKN2A, 1.3-fold for CDKN2B, and 2-fold for ANRIL. Risk SNPs for coronary disease, stroke,
diabetes, melanoma, and glioma were all associated with allelic expression of ANRIL (all P,0.05 after correction for multiple
testing), while association with the other two genes was only detectable for some risk SNPs. SNPs had an inverse effect on
ANRIL and CDKN2B expression, supporting a role of antisense transcription in CDKN2B regulation. Our study suggests that
modulation of ANRIL expression mediates susceptibility to several important human diseases.
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Introduction
The chromosome9p21.3 region adjacent to the loci encodingthe
cyclin-dependent kinase inhibitors CDKN2A (ENSG00000147889)
and CDKN2B (ENSG00000147883) is an important susceptibility
locus for several diseases with a complex genetic background.
Recent genome-wide association (GWA) studies have shown that
singlenucleotidepolymorphisms(SNPs) inthis regionareassociated
with coronary artery disease (CAD) [1–4], ischaemic stroke [5,6],
aortic aneurysm [7], type II diabetes [8,9], glioma [10,11], and
malignant melanoma [12]. Candidate gene approaches have also
reported SNPs in this region to be associated with breast [13,14],
ovarian [15], and pancreatic carcinoma [16], melanoma [17], and
acute lymphoblastic leukaemia [18], as well as with poor physical
function in the elderly [19]. Variants associated with these diseases
are represented in Figure 1. Most of the risk variants in the
chromosome 9p21 region identified by GWA studies are in non-
coding regions, suggesting that their effects are likely to be mediated
by influences on gene expression. Sequence variation can influence
expression by cis or trans mechanisms. Trans-acting elements
influence transcript levels of both alleles via diffusible factors and
are usually located distant to the genes they regulate, whereas cis-
acting elements act on genes on the same chromosome in an allele-
specific manner and are usually located close to the genes they
regulate. Since most reported risk variants in the 9p21 region do not
appear in mature transcripts, and there are no known or predicted
microRNAs mapping to this region [20–23], these variants are
unlikely to produce diffusible trans-acting factors and are therefore
likely to influence expression of nearby genes in cis. Genes in the
region include the cyclin-dependent kinase inhibitors CDKN2A
(p16
INK4a) including its alternative reading frame (ARF) transcript
variant (p19
ARF), CDKN2B(p15
INK4b), and arecently-discovered non-
codingRNA,designated ANRIL(CDKN2BAS,ENSG00000240498),
that undergoes splicing and is transcribed from the opposite strand
to CDKN2A/B. The ARF/CDKN2A/B proteins are established
tumour suppressors deleted in a range of cancers including familial
cutaneous malignant melanoma [24]; they block cell cycle
progression and influence key physiological processes such as
replicative senescence, apoptosis, and stem-cell self-renewal [25].
Cis-actingregulatoryelementsforthesegeneshavebeenidentifiedin
vitro using reporter assays [26–30], but expression levels are also
influenced by factors such as age, chemotherapeutic agents, DNA
damage by ultraviolet or ionizing radiation, and levels of
transcriptional regulators [31], all of which are likely to act in trans.
PLoS Genetics | www.plosgenetics.org 1 April 2010 | Volume 6 | Issue 4 | e1000899The function of ANRIL is unknown, but other processed non-coding
RNAs are involved in the regulation of gene expression through
transcriptional and translational control mechanisms [32].
Genetic effects on expression can be assessed by comparing total
expression levels in individuals with different genotypes at a
putative regulatory locus. This is termed expression quantitative
trait locus (eQTL) mapping [33]. This approach utilises informa-
tion from all members of the population, but reflects the net effect
of both cis and trans-acting influences; the sensitivity to detect cis-
acting effects is therefore reduced in the presence of significant
variation in trans-acting influences such as the environmental
factors outlined above. An alternative approach that is specific for
mapping cis-acting influences is to measure allelic expression
(aeQTL mapping). An unequal amount of transcript arising from
each allele in an individual heterozygous for a transcribed
polymorphism indicates the presence of cis-acting effects on
expression. While traditional eQTL analysis assesses the influence
of polymorphisms by comparing expression between samples,
allelic expression analysis compares the expression levels of alleles
within individual samples, making it much more robust to trans-
acting influences that affect both alleles such as age, gender,
population stratification, or experimental variability. This maxi-
mises the sensitivity for detecting cis-acting effects [34].
Variants associated with CAD span a region greater than
100kb, but the association is accounted for by SNPs within a 53kb
interval that define a core risk haplotype [35]. Lead SNPs for CAD
and diabetes are in separate LD blocks in Caucasians and are
independently associated with the two separate diseases [35]. To
date, CAD risk SNPs have shown inconsistent association with
CDKN2A, CDKN2B and ANRIL by eQTL mapping. One CAD risk
SNP was associated with altered ANRIL expression in blood, but
not with CDKN2A or CDKN2B expression [36], whilst a different
CAD risk SNP has been associated with reduced expression of all
three genes in peripheral blood T-cells [37]. However, the latter
study found no association with expression for other CAD risk
SNPs [37], and another report also found no association of a lead
CAD risk SNP with these genes or with global gene expression in
primary vascular tissue and lymphoblastoid cells [38]. Based on
evolutionary conservation and effects on expression, individual
SNPs (rs10757278 and rs1333045) have been highlighted as
potential causal variants for the association with CAD [36,37].
However, if multiple cis-acting effects are present at a locus,
resolving a disease association by fine-mapping may not be
possible. Examining gene expression rather than disease pheno-
type increases the power to map cis-acting effects, and we used this
approach to determine whether multiple sites independently
influence expression. Caucasian populations have strong linkage
disequilibrium (LD) in the chromosome 9p21 region which limits
the ability to separate the effects of individual SNPs on expression
[35]. Populations of African ancestry have less LD [39,40], which
can be exploited to improve the fine-mapping of functional
polymorphisms associated with quantitative traits [41,42].
We therefore used eQTL and aeQTL mapping to perform
detailed fine-mapping of the association of SNPs at the 9p21.3
locus with expression of CDKN2A, CDKN2B and ANRIL using a
mixed-ancestry South African (SA) population, as well as a British
Caucasian cohort. We identified multiple SNPs independently
associated with expression of each gene, suggesting that several
sites may modulate disease susceptibility. The markers identified in
GWA studies were all associated with allelic expression of ANRIL,
Figure 1. SNPs associated with disease in the chromosome 9p21.3 region. Genes are illustrated in blue at the top, with arrows representing
the direction of transcription. SNPs typed in our study and SNPs associated with various diseases are represented by black bars. Diseases in bold are
those with association data from genomewide association studies. The hatched box represents the core risk haplotype for CAD defined by Broadbent
et al [35]. Promoter regions for each gene are shown as pale blue boxes. DM=diabetes mellitus type II; BCC=basal cell carcinoma.
doi:10.1371/journal.pgen.1000899.g001
Author Summary
Genetic variants on chromosome 9p21 have been
associated with several important diseases including
coronary artery disease, diabetes, and multiple cancers.
Most of the risk variants in this region do not alter any
protein sequence and are therefore likely to act by
influencing the expression of nearby genes. We investi-
gated whether chromosome 9p21 variants are correlated
with expression of the three nearest genes (CDKN2A,
CDKN2B, and ANRIL) which might mediate the association
with disease. Using two different techniques to study
effects on expression in blood from two separate
populations of healthy volunteers, we show that variants
associated with disease are all correlated with ANRIL
expression, but associations with the other two genes are
weaker and less consistent. Multiple genetic variants are
independently associated with expression of all three
genes. Although total expression levels of CDKN2A,
CDKN2B, and ANRIL are positively correlated, individual
genetic variants influence ANRIL and CDKN2B expression in
opposite directions, suggesting a possible role of ANRIL in
CDKN2B regulation. Our study suggests that modulation of
ANRIL expression mediates susceptibility to several impor-
tant human diseases.
ANRIL Expression and Disease Associated SNPs
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some of them. Our study suggests that modulation of ANRIL
expression mediates susceptibility to a range of important human
diseases.
Results
We measured expression of CDKN2A, CDKN2B and ANRIL in
peripheral blood from 310 healthy SA individuals (demographic
details provided in the Methods section). Allelic expression was
assessed for each gene using two transcribed SNPs located within
the same exon. We selected 56 SNPs that tag the common
variation in the region, specifically including SNPs with previously
reported phenotypic associations. The results of allelic expression
mapping in this population were compared with conventional
mapping using total expression in the same samples; and with
allelic expression mapping in a separate population of 177 healthy
British Caucasians. Information on the selected SNPs and
genotyping data are summarised in Table S1.
Inter-individual variation in expression
Total expression levels showed substantial inter-individual
variation for each of the three genes, up to 13.9-fold for CDKN2A,
36.1-fold for CDKN2B, and 25.5-fold for ANRIL. Allelic expression
ratios at individual transcribed markers also showed considerable
inter-individual variation, up to 5.6-fold for CDKN2A, 2.4-fold for
CDKN2B, and 6.8-fold for ANRIL. Plots of the allelic expression
ratios at each transcribed SNP in the SA and Caucasian cohorts
are shown in Figure S1 and Figure S2 and plots of the normalised
total expression Ct values are shown in Figure S3. Standard errors
for ANRIL were higher than for the other two genes in both the
allelic and total expression assays, which is likely to be due to the
fact that peripheral blood expression of ANRIL was lower than for
CDKN2A and CDKN2B.
We estimated the proportion of the variance in total expression
that can be attributed to cis-acting effects for each transcribed SNP
in the three genes, as described in the Methods section. For
CDKNA this proportion was 8% when rs3088440 was used to
estimate the variance in cis acting effects, and 4% when rs11515
was used. For CDKN2B the corresponding values were 5% (using
rs3217992), 5% (using rs1063192) and for ANRIL 20% (using
rs10965215), and 19% (using rs564398).
Correlation of CDKN2A, CDKN2B, and ANRIL expression
Total expression levels of CDKN2A, CDKN2B and ANRIL
were positively correlated (r=0.24 to 0.30, all P,4610
25)a s
shown in Figure S4, suggesting that expression of these genes is
co-regulated.
Allelic expression versus total expression for mapping
cis-acting effects
Allelic expression ratios (AER) measured at the two transcribed
SNPs in each gene were highly correlated (CDKN2A r=0.68
P=1.7610
23; CDKN2B r=0.80 P=1.7610
212; ANRIL r=0.90
P=1.0610
226; all genes combined r=0.96 P=3610
261)a s
shown in Figure S5. This was expected since the two transcribed
SNPs selected to assess AER in each gene are located in the same
exon and the same transcripts. We therefore used the AERs from
both transcribed markers in each gene (as described in the
Methods section) for the aeQTL analysis. This increased the
number of informative heterozygotes at which allelic expression
could be assessed for each gene and increased the power to detect
significant effects, as shown in Table 1.
Unlike allelic expression ratios, total expression data may be
influenced by covariates that influence expression in trans.W e
therefore corrected total expression values for covariates (age, sex,
and ethnicity) and excluded outlying individuals as described in
the Methods section. These corrections did not significantly alter
the results of the eQTL analysis, as shown in Figure S6. All
subsequent analyses are presented using the covariate-corrected
eQTL data. We compared cis-acting effects assessed by eQTL and
aeQTL mapping, as shown in Figure 2. There was a strong
correlation both for the effect size (r=0.87, P=4.7610
251) and
significance of association (r=0.97, P=4.8610
299) at each
mapping SNP between the two techniques. However, the
associations were more significant for allelic expression than for
total expression analysis, indicating that allelic expression had
greater power for detecting cis-acting effects. This suggests that
trans-acting effects make a substantial contribution to the overall
variance of expression in these genes, which is consistent with our
Table 1. Increase in number of informative heterozygotes and associated SNPs using two transcribed SNPs per gene.
Transcribed SNP
Number (%) of
informative
heterozygotes in
Caucasian cohort
(n=177)
Number (%) of
informative
heterozygotes in
SAcohort (n=310)
Number (%) of mapping
SNPs significantly associated
with AER at transcribed SNP(s)
in Caucasian cohort*
(n=53 SNPs)
Number (%) of mapping
SNPs significantly associated
with AER at transcribed
SNP(s) in SA cohort*
(n=56 SNPs)
CDKN2A rs3088440 23 (12%) 103 (33%) 5 (9%) 2 (4%)
CDKN2A rs11515 33 (18%) 75 (24%) 0 (0%) 9 (16%)
CDKN2A markers combined 54 (29%) 159 (51%) 3 (6%) 11 (20%)
CDKN2B rs3217992 71 (38%) 112 (36%) 0 (0%) 4 (7%)
CDKN2B rs1063192 70 (37%) 87 (28%) 0 (0%) 2 (4%)
CDKN2B markers combined 90 (48%) 164 (53%) 5 (9%) 5 (9%)
ANRIL rs10965215 70 (37%) 155 (50%) 25 (47%) 27 (48%)
ANRIL rs564398 67 (36%) 85 (28%) 23 (43%) 22 (39%)
ANRIL markers combined 80 (43%) 187 (61%) 30 (57%) 31 (55%)
*Multiple testing was taken into account by calculating the family wise error rate using a Bonferroni correction for the 56 SNPs tested. Associations with family wise
error rate using a threshold of 0.05 (that corresponds to a nominal P value of 8.9610
24 or 2log10P of 3.05) were called significant. SNPs with less than 8 informative
heterozygotes were excluded.
doi:10.1371/journal.pgen.1000899.t001
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PLoS Genetics | www.plosgenetics.org 4 April 2010 | Volume 6 | Issue 4 | e1000899estimates that cis-acting effects account for only between 4 and
20% of the overall variance in expression of these genes.
Comparison of cis-acting effects between populations
and combined analysis
We compared aeQTL analysis between the SA and British
Caucasian samples. Results of aeQTL mapping were highly
correlated between the two populations, both for the significance
of the detected association (r=0.94, P=10
272) and the estimated
magnitude of the effect on expression for each SNP (r=0.82,
P=2 610
238), as shown in Figure 3. Patterns of LD in the two
populations are shown in Figure S7. Minor allele frequency in the
SA population was higher (which increases the proportion of
informative heterozygotes for allelic expression analysis) for 33 of
the 53 SNPs typed in both populations.
In view of the similarity of the effects in the two cohorts, we
combined the data in subsequent analyses, increasing the power to
detect cis-acting effects of smaller magnitude and enabling us to adjust
for the effects of individual SNPs. The significance of associations for
individual SNPs in the combined cohort is shown in Figure 4.
Subsequent results refer to the combined dataset, with specific
discussion of differences between the populations where relevant.
As described in the Methods section, we defined significance
thresholds for all SNP associations using the family wise error rate
(FWER) where multiple testing was taken into account by using a
Bonferroni correction for the 56 SNPs tested. Associations with a
FWER threshold of 0.05 (corresponding to a nominal P-value of
8.9610
24, 2log10P of 3.05, and 2log10 FWER of 1.3) were
regarded as significant. Table S2 shows the 2log10 of the nominal
P-values and FWER for all SNP associations, and nominal
P-values are reported in the text.
The effect of each SNP on AER is also shown in Table S2. The
maximum change in allelic expression associated with any SNP
was 1.4-fold for CDKN2A, 1.33-fold for CDKN2B, and 1.97-fold for
ANRIL. Due to the power of our combined dataset we were able to
detect SNP effects on allelic expression as small as 1.05-fold that
were significant.
Multiple sites influence CDKN2A, CDKN2B, and ANRIL
expression
As shown in Figure 4, multiple SNPs were associated with cis-
acting influences on expression of CDKN2A, CDKN2B and ANRIL.
This could be the result of multiple independent loci influencing
expression of each gene, but could also be a reflection of strong LD in
the region since associations might be observed for ‘non-functional’
SNPs (that do not directly influence expression) which are in LD with
other ‘functional’ polymorphisms. Adjusting for the effect of
individual SNPs was used to assess whether multiple SNPs were
independently correlated with expression of the three genes, as shown
in Figure 5. For each gene stepwise adjustments were made for the
effect of the SNP which showed the most significant association with
expression, until independent effects could no longer be detected.
Associations remained significant after adjusting for the top SNP for
CDKN2A and CDKN2B,a n dt h et o pt w oS N P sf o rANRIL.
Our results indicate that even after adjusting for the effects of the
most significant marker, some of the remaining SNPs still showed
significant association with ANRIL expression. This could be
explained by the presence of more than one functional polymor-
phism affecting expression, but could also reflect the presence of a
functional polymorphism that is in disequilibrium with both
markers. However, examination of the allelic expression patterns
provides additional support for the presence of multiple sites
affecting expression. For example, Figure 6 shows the allelic
expression ratios observed at the transcribed SNP rs564398 in
ANRIL, grouped according to the genotype at rs10965215. These
two SNPs are in strong LD (D9=0.98), hence the absence of
individuals homozygous for the A allele at rs10965215 that are
heterozygous at rs564398. We observe that the G allele of the
transcribed SNP (rs564398) is overexpressed (G/A AER values
greater than 1), however overexpression is stronger (P=10
215 using
the Mann-Whitney test) for individuals that are also heterozygous at
the second polymorphism (rs10965215). This pattern is not
consistent with allelic expression being determined by a single
biallelic polymorphism acting in cis and suggests that there is more
than one functional polymorphism or that this polymorphism is
multiallelic. Such patterns were common in our data.
The direction of cis-acting effects on expression was compared
between genes for SNPs showing significant associations with
expression of each gene, as shown in Table 2. SNP effects for
CDKN2A and ANRIL were in the same direction for all 10 SNPs,
meaning that alleles associated with overexpression of CDKN2A
were also associated with overexpression of ANRIL. By contrast,
for all 8 SNPs that were significantly associated with allelic
expression of both CDKN2A and CDKN2B, the alleles associated
with CDKN2A overexpression were associated with CDKN2B
underexpression. Similarly for all 3 SNPs significantly associated
with allelic expression of both CDKN2B and ANRIL, alleles
associated with overexpression of CDKN2B were associated with
ANRIL underexpression. The total expression analysis had
insufficient power for similar analyses to be performed.
In vivo effects of putative regulatory elements identified
in vitro
We investigated whether SNPs within regulatory regions
previously identified by in vitro reporter assays were associated
with cis-acting effects on expression in vivo. The effect on gene
expression and significance of the association for each SNP is
summarised in Table S2.
CDKN2A expression was significantly correlated with SNPs in its
promoter and the ARF transcript promoter [26–29], and with
SNPs close to the RD
INK4/ARF domain that has been shown to
regulate expression of CDKN2A, ARF and CDKN2B in vitro [30].
CDKN2B expression was also significantly correlated with SNPs
in the CDKN2A and ARF promoter regions, suggesting that these
elements influence expression of both genes. CDKN2B expression
was not significantly correlated with the single SNP typed in its
promoter (rs2069418) prior to adjustment, but this became
significant after adjustment for the most significant SNP in the
ARF promoter (rs3218018).
ANRIL expression was strongly associated with SNPs in the
CDKN2B promoter (P=10
272), ARF promoter (P up to10
253) and
RD
INK4/ARF domain (P=10
212), as well as with SNPs adjacent to
the CDKN2A promoter (rs3731239, P=10
225).
Figure 2. Significance of associations and effect size estimates using total and allelic expression. Scatter plots depict the P-values (A)
and estimates of effect size (B) obtained for each SNP for all three genes by eQTL (X-axis) and aeQTL (Y-axis) mapping. Bar charts show the
comparison of the significance of association for CDKN2A (C), CDKN2B (D), and ANRIL (E); and the effect size estimates for CDKN2A (F), CDKN2B (G), and
ANRIL (H). The Y-axes on the bar charts show the 56 SNPs ordered by chromosome location (most telomeric at the top). Grey bars to the left represent
total expression and black bars to the right represent allelic expression.
doi:10.1371/journal.pgen.1000899.g002
ANRIL Expression and Disease Associated SNPs
PLoS Genetics | www.plosgenetics.org 5 April 2010 | Volume 6 | Issue 4 | e1000899These data validate in vivo the function of the regulatory
elements identified by in vitro transfection studies, and confirm that
shared cis-acting elements influence expression of CDKN2A,
CDKN2B and ANRIL.
CAD, diabetes, and cancer risk variants are associated
with cis-acting effects on expression
We examined the correlation of allelic expression of
CDKN2A, CDKN2B and ANRIL with SNPs reported to confer
disease susceptibility. The effect on gene expression and
significance of the association for each SNP is summarised in
Table 3.
CAD and stroke. SNPs within the core risk haplotype region
for CAD [35] were associated with ANRIL expression (P up to
10
221), but none were associated with CDKN2A or CDKN2B
expression. CAD risk alleles were all associated with reduced
ANRIL expression, up to 1.9-fold, suggesting that expression of
ANRIL, rather than CDKN2A or CDKN2B, might mediate
atherosclerosis susceptibility. However, other CAD risk variants
located telomeric to the core risk haplotype region such as
Figure 3. SNP effects in the SA and Caucasian cohorts. Scatter plots show the correlation between aeQTL results obtained in the SA (Y-axis)
and Caucasian cohorts (X-axis) for: (A) significance of association with expression (2log P value) for all three genes; (B) effect size at each SNP for all
three genes; (C) effect size at each SNP for CDKN2A only; (D) effect size at each SNP for CDKN2B only; (E) effect size at each SNP for ANRIL only. Linear
regression line for the association is shown as a solid line with the 95% confidence intervals shown as dotted lines.
doi:10.1371/journal.pgen.1000899.g003
ANRIL Expression and Disease Associated SNPs
PLoS Genetics | www.plosgenetics.org 6 April 2010 | Volume 6 | Issue 4 | e1000899Figure 4. Significance of association with expression for SNPs in the combined population. The Y-axis represents the 2log P value for
individual SNPs (shown in chromosomal order along the X-axis) for: CDKN2A (A); CDKN2B (B); ANRIL (C). The horizontal black line on each graph
represents the significance threshold after adjustment for multiple testing (family wise error rate of 0.05 corresponding to 2log10P=3.05). The
relative location of genes and promoter elements is represented at the top (CDKN2A and CDKN2A/ARF promoters yellow; ANRIL promoter blue;
CDKN2B promoter orange; CDKN2A/ARF regulatory domain red). Letters along the bottom represent associations from GWA studies (C=CAD,
D=diabetes, M=melanoma, G=glioma) and the black bar at the bottom represents the core risk haplotype for CAD defined by Broadbent et al [35].
doi:10.1371/journal.pgen.1000899.g004
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stronger associations with ANRIL expression (P,10
260 for each
SNP), and were also significantly associated with CDKN2A and
CDKN2B expression (P,10
24 for each SNP). The CAD risk alleles
at these SNPs correlated with reduced expression of ANRIL and
CDKN2A, but increased CDKN2B expression. Associations for
these SNPs remained significant after adjusting for the effect of the
lead CAD SNPs within the core risk haplotype region
(rs10757274, rs2383206, rs10757278 and rs1333049) [35], but
SNPs within the core risk haplotype were no longer significantly
associated with ANRIL expression after adjusting for the effect of
SNPs at the distal locus (rs10965215 and rs564398). This suggests
that the core CAD risk haplotype does not account for all of the
observed association with ANRIL expression in peripheral blood.
Based on evolutionary conservation and effects on ANRIL
transcription, rs1333045 within the core risk haplotype has been
previously highlighted as a potential functional variant responsible
for conferring susceptibility to CAD at the 9p21 locus [36]. In our
analysis rs1333045 was associated with ANRIL expression
(P=10
212), but not with CDKN2A or CDKN2B expression. Its
effects were similar to those of other SNPs in the core risk
haplotype for CAD. After adjusting for the effect of rs1333045, 32
SNPs remained significantly associated with ANRIL expression,
suggesting that the effect attributed to such variants was not due to
LD with rs1333045.
Diabetes. The lead chromosome 9p21 SNPs associated with
diabetes in GWA studies are located in a separate LD block to the
CAD risk variants [7,9], and the phenotypic effects of CAD and
diabetes variants have been shown to be independent [35].
Diabetes risk alleles in this region (rs10811661-T and rs2383208-
A) were associated with under-expression of ANRIL, but were not
associated with CDKN2A or CDKN2B expression in our Caucasian
population. However, these SNPs showed no association with
expression of ANRIL in the SA population, despite greater power
to detect effects in this cohort.
A separate locus for diabetes susceptibility in the chromosome
9p21 region in Caucasians is located within the region associated
with CAD risk. The rs564398-T risk allele at this locus is
associated with diabetes [8], CAD [35] and stroke [5]. This SNP
had the strongest association with ANRIL expression of all the
SNPs we tested (P=10
281), but was not significantly associated
with CDKN2A or CDKN2B expression. The rs564398-T risk allele
was associated with ANRIL underexpression, and the association
remained significant after adjusting for the effect of rs10811661,
the lead diabetes SNP. However, the association with rs10811661
was no longer significant after adjustment for rs564398.
Figure 5. Effect of sequential adjustment for most highly associated SNPs. Bars represent the significance of association (2log10P) for each
SNP. (A) Unadjusted. (B) Adjusted for the most highly associated SNP for each gene (CDKN2A rs7036656, CDKN2B rs3218018, ANRIL rs564398). (C)
Adjusted for the two most highly associated SNPs for each gene (CDKN2A rs7036656 and rs36228834, CDKN2B rs3218018 and rs3814960, ANRIL
rs564398 and rs10965215). Values in the top right corner are the number of significantly associated SNPs after each round of adjustment, following
correction for multiple testing. The horizontal black line on each graph represents the significance threshold after adjustment for multiple testing
(family wise error rate of 0.05 corresponding to 2log10P=3.05).
doi:10.1371/journal.pgen.1000899.g005
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chromosome 9p21 SNPs correlated with susceptibility for glioma
[10,11] and malignant melanoma [12]. The glioma risk allele
rs1063192-C was highly correlated with increased ANRIL
expression (P=10
261), while the melanoma risk variant
rs1011970-T correlated with reduced expression of ANRIL.
Neither was associated with CDKN2A or CDKN2B expression.
Multiple candidate gene association studies have reported
associations between SNPs in this region and susceptibility to a
variety of diseases. These have mostly involved cancer phenotypes
because the cell-cycle regulators CDKN2A and CDKN2B are
recognised to be involved in predisposition to certain cancers.
Such association studies have implicated 9p21 SNPs as being
potentially involved in the development or therapeutic response to
pancreatic [16,43], breast [13,14,44], ovarian [15,45], and
bladder [46] carcinoma, as well as acute lymphoblastic leukaemia
[18], and melanoma [17,47,48]. The SNPs associated with these
phenotypes showed a significant correlation with allelic expression
of one or more of the genes we examined, as summarised in
Table 3. A SNP (rs2811712) that is associated with severely limited
physical function in older people [19] was significantly associated
with CDKN2B expression, but not with ANRIL expression.
Discussion
This is the most detailed study to date of cis-acting influences on
expression at the chromosome 9p21 locus. We have shown that
multiple sites in the 9p21 region independently influence CDKN2A,
CDKN2B and ANRIL expression, and demonstrated that SNPs
associated with diseases including CAD, diabetes, and cancers are
all highly associated with ANRIL expression, suggesting that
modulation of ANRIL expression may mediate disease susceptibil-
ity. We also report novel methodology for allelic expression
analysis that allowed us to combine data from multiple transcribed
polymorphisms and to adjust for the effects of particular SNPs. We
have demonstrated that this approach has greater power than total
expression analysis for mapping cis-acting effects.
Total expression levels of CDKN2A, CDKN2B and ANRIL, which
reflect the combined influence of cis and trans-acting factors, were
positively correlated. This corroborates other recent data [37], and
suggests that expression of these genes is co-regulated. We have
shown that trans-acting influences account for the majority of the
observed variance in expression of these genes (80–96%), and the
correlation in total expression levels is likely to reflect co-regulation
of the genes through trans-acting factors. In addition, our allelic
expression analysis demonstrated that expression is also influenced
by shared cis-acting elements in the region. Despite the positive
Figure 6. Effect of genotype at rs10965215 on allelic expression ratio of transcribed ANRIL SNP rs564398. Diamonds represent the
allelic expression ratio for each individual, all of whom are heterozygous for the transcribed SNP rs564398. The first column shows individuals who are
homozygous for rs10965215 (mean ratio 1.57), and the second column shows individuals who are heterozygous for rs10965215 (mean ratio 2.00). The
third column shows the expression ratio obtained from genomic DNA in individuals who are heterozygous for the transcribed SNP rs564398, where
the two alleles are present in a 1:1 ratio (mean ratio 1.00).
doi:10.1371/journal.pgen.1000899.g006
Table 2. Correlation of SNP effects between genes by aeQTL
mapping.
CDKN2A-
ANRIL
CDKN2B-
ANRIL
CDKN2A-
CDKN2B
SNP effects same direction 10 0 0
SNP effects opposite 038
The table shows the SNP effect between genes for SNPs that show significant
association (using family wise error rate threshold 0.05) with expression of both
genes. Gene pairs are shown along the top. SNP effects in the same direction
means that a SNP is associated with overexpression or underexpression of both
genes, whereas SNP effects in the opposite direction means that a SNP
associated with underexpression of one gene is associated with overexpression
of the other gene.
doi:10.1371/journal.pgen.1000899.t002
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PLoS Genetics | www.plosgenetics.org 10 April 2010 | Volume 6 | Issue 4 | e1000899correlation in total expression levels, cis-acting effects associated
with individual SNP alleles may act in opposite directions; the
effect of individual SNPs on CDKN2B expression were opposite to
effects on CDKN2A and ANRIL expression (which were concor-
dant) in our study. Because cis-acting effects represent only a small
proportion of the overall variance in expression of these genes, the
effects acting in trans are likely to account for the positive
correlation seen in total expression, but this does not diminish the
potential biological significance of the cis-acting effects. ANRIL
overlaps and is transcribed in antisense with respect to CDKN2B
[49]. It is modestly conserved across species [36] and its function is
not known, but recent work has demonstrated that antisense
transcription from CDKN2B downregulates CDKN2B expression in
cis through heterochromatin formation [50]. This is consistent with
our observation of an inverse effect of SNPs on ANRIL and
CDKN2B expression. By contrast, CDKN2A and ANRIL showed
positive correlations for both allelic and total expression in our
study. CDKN2A and ANRIL do not overlap, but are transcribed
divergently from transcription start sites separated by just 300 base
pairs. Although the ANRIL promoter is currently not charac-
terised, it may share promoter elements with CDKN2A and the
resulting co-regulation could account for the positive correlation in
expression we observed for these genes, similar to that described at
other sites [51]. In this context, inhibition of CDKN2B expression
by ANRIL would enable a level of crosstalk between CDKN2A and
CDKN2B expression, which would be consistent with the inverse
cis-acting effect of SNPs on CDKN2A and CDKN2B that we
observed. The observation that cis-acting genetic effects played a
greater role in expression of ANRIL compared to CDKN2A and
CDKN2B (20% compared to less than 8% and 5% respectively)
makes it a good candidate for genetic causation mediated through
influences on expression.
We compared total expression and allelic expression for the
investigation of cis-acting influences on expression. While tradi-
tional eQTL analysis assesses the influences of polymorphisms by
comparing expression between samples, allelic expression analysis
compares the expression levels of alleles within individual samples,
making it more robust to influences that affect both alleles such as
age, gender or population stratification. This offers an important
advantage for dissecting such cis-acting influences on expression,
which although of lesser magnitude than trans-acting influences,
may be of biological importance and possibly account for the
genetic susceptibility observed in recent GWA studies. For aeQTL
mapping we used a novel adaptation of our previously reported
methodology [52] to combine multiple transcribed SNPs per gene,
which increased the number of informative individuals and the
power for detecting cis-acting effects. We demonstrated this
approach using two transcribed polymorphisms per gene, but
our methodology offers the potential for the inclusion of multiple
additional transcribed variants. The results obtained by eQTL and
aeQTL mapping were similar, consistent with previous work
suggesting that the two approaches identify the same cis-acting loci
[42]. However, we demonstrated that aeQTL analysis had
substantially greater power than the eQTL approach. Adjusting
for trans-acting covariates including age, sex and ethnicity in our
eQTL analysis did not substantially alter the results. An influence
of age on CDNK2A has been reported [53], but there was little
variability in the age of our SA cohort (90% of whom were
between the ages of 18 and 30 years). The fact that allelic
expression is a more efficient way to identify cis-acting influences
on expression has implications for future studies investigating the
effects of SNPs on expression at other loci, for example for the
hundreds of non-coding SNPs correlated with different diseases by
recent GWA studies [54].
Allelic expression quantifies the relative contributions of each
allele to the mRNA pool irrespective of the absolute mRNA levels,
and therefore provides information about transcriptional effects
and polymorphisms within the transcript influencing RNA
degradation in cis. By contrast, total expression analyses that
quantify absolute mRNA levels are also sensitive to post-
transcriptional regulatory effects, such as mRNA degradation by
microRNAs. In extreme cases tight post-transcriptional regulation
could keep total mRNA levels constant irrespective of the
contributions of each allele to the total mRNA pool. The fact
that the results of eQTL and aeQTL mapping were so similar in
our study suggests that the effect of regulation at the post-
transcriptional level is limited, although regulation of CDKN2A
expression by a microRNA has been described [55]. In general,
although allelic expression is a robust method for mapping sites
influencing expression in cis, investigation of total expression and
other intermediate phenotypes such as protein levels or protein
activity will provide complementary information that contributes
to fully understanding the phenotypic effects of cis-acting
polymorphisms. It would be desirable to determine whether the
significant associations with mRNA expression observed for
CDKN2A and CDKN2B are confirmed at the protein level.
Although we had hoped to use trans-ethnic fine-mapping to
refine the associations with expression, the results of aeQTL
mapping were in fact very similar in the SA and Caucasian
populations. This replication in a separate cohort strongly supports
the validity of our findings and enabled us to perform a combined
analysis of the two cohorts. This approach of pooling data from
ethnically-divergent populations has been previously shown to
increase the power to detect influences on expression that are
shared across populations [42,56]. The principal difference we
identified between the two populations was for the SNPs
associated with type II diabetes. The lead diabetes SNP
rs10811661 was correlated with ANRIL underexpression in the
Caucasian cohort, but not in the SA population, despite greater
power to detect effects in that cohort. This may reflect differences
in LD between the populations, but suggests that rs10811661 may
not itself be the causal variant influencing diabetes susceptibility
through effects on ANRIL expression. Studies to determine
whether this SNP is associated with diabetes in populations of
African origin would be of interest.
The power of our analyses to detect differences in expression
enabled us to adjust for the effects of individual SNPs. Using this
we were able to demonstrate that expression, and therefore
probably disease predisposition, is independently influenced by
multiple sites and that the observed effects cannot be explained by
a single polymorphic site. From our analysis we cannot exclude the
existence of rare variants with large effects, but previous
resequencing studies in this region did not find rare variants
associated with disease phenotypes [2,3]. We are unable to say
whether the individual SNPs for which we found associations are
the actual ‘causal’ variants responsible for the effects on
expression, or if the association simply reflects linkage disequilib-
rium between these SNPs and the causative polymorphisms.
Although fine mapping studies often purport to identify causal
variants, in the context of complex diseases characterising the
pathways involved in disease predisposition may be more
important. This is of particular interest for these genes where
variation in expression is mostly due to trans effects which may be
substantially influenced by non-genetic factors, raising the
prospect that it may be amenable to therapeutic modulation.
The putative causal variants rs10757278 and rs1333045 previously
associated with altered ANRIL expression [36,37] were signifi-
cantly associated with reduced ANRIL expression in vivo in our
ANRIL Expression and Disease Associated SNPs
PLoS Genetics | www.plosgenetics.org 11 April 2010 | Volume 6 | Issue 4 | e1000899analysis, but their effects were relatively modest compared to other
SNPs in the region and adjustment for the effect of these SNPs
accounted for only a small proportion of the effect observed at
other SNPs. The maximum changes in expression associated with
individual SNPs were substantial, up to 2-fold for ANRIL, but we
were also able to detect effects of much smaller magnitude; the
minimum significant effect was associated with just a 1.05-fold
change in expression. Although the associations of SNPs with
expression that we observed were statistically highly significant, we
cannot say what impact such effects on expression have on disease
risk. However, even small differences in gene expression due to
genetic factors that are present throughout an individual’s lifetime
could contribute to differences in common late-onset phenotypes
such as CAD and diabetes, and the effects may be even greater in
tissues related to disease.
We examined in vivo expression in primary cells rather than in
transformed cell lines. Although cell lines have been extensively
used to investigate cis-acting influences on expression [56,57],
patterns of expression may be altered in immortalised cells,
particularly for genes such as these that are associated with
senescence and cell-cycle regulation. Furthermore, widely used
cell lines are pauciclonal or monoclonal [58,59] and since a
significant proportion of human genes exhibit random patterns of
monoallelic expression within single clones of cell lines [60], cis-
acting effects in these cells are unlikely to be representative of
polyclonal cell populations in vivo. Previous studies have
delineated the promoters and other elements regulating
CDKN2A/ARF and CDKN2B expression using reporter assays
[26–30]. Such studies are valuable to identify causative
polymorphisms, but since they examine the effects on expression
outside of the normal haplotype, chromatin and cellular context
their findings require confirmation by in vivo studies [34,61]. Our
analysis confirmed that polymorphisms in upstream regulatory
elements identified by in vitro assays were significantly associated
with cis-acting effects on expression in vivo, but we also
demonstrated that other loci located up and downstream were
associated with effects on expression of similar or even larger
magnitude. These data highlight the complexity and multiplicity
of sites influencing expression in the region. The assays we used
to investigate CDKN2A expression also included the ARF
transcript variant. This gave the possibility to detect sites
influencing expression of both transcripts, and we were able to
detect effects of SNPs in both the CDKN2A and ARF promoter
regions, although differential effects of loci on individual
transcripts cannot be distinguished using this approach.
All of the SNPs in the region associated with disease in GWA
studies were associated with influences on ANRIL expression,
suggesting that modulation of ANRIL expression may mediate
susceptibility to these phenotypes. SNPs in the CAD core risk
haplotype region [35] that are most strongly associated with
CAD in GWA studies were associated with reduced ANRIL
expression, but other SNPs associated with CAD which lie
outside of the core risk haplotype showed independent and
stronger associations with ANRIL underexpression. This may
reflect differences in the relative importance of particular sites in
the tissues responsible for the association with CAD. Indeed, the
patterns of association we have observed in peripheral blood in
healthy individuals may differ from those in primary disease
tissues. Similarly, differences in the relative contribution of each
SNP to modulation of expression in the tissues crucial for the
pathogenesis of the different conditions could explain why
particular diseases are associated with different subsets of SNPs
that influence ANRIL expression. Recent work also suggests that
ANRIL has multiple transcripts, which may be differentially
expressed between tissues [36,38]. Confirmation of our findings
in tissues relevant to each disease and for different ANRIL
transcripts would therefore be desirable, although for CAD and
other complex diseases the cell populations responsible for
mediating disease susceptibility are unknown and may be
inaccessible. Although tissue specificity of cis-acting influences
is well documented, variation in cis-acting effects is primarily
explained by genetic variation, with allele-specific expression at
most SNPs being the same between tissues in the same individual
[62]. Analysis of expression in blood is therefore likely to give
biologically relevant information despite the fact that this may
not be the tissue in which influences on expression actually
mediate disease susceptibility.
Previous genomewide expression analyses using microarrays
and immortalised cell lines did not identify association of CDKN2A
and CDKN2B expression with markers in this region, although they
did not examine ANRIL expression [56,57]. However, two recent
studies specifically examining expression in the chromosome 9p21
region in primary cells reported associations between CAD risk
SNPs and gene expression in blood [36,37]. Jarinova et al found
significant association of CAD risk variant rs1333045-C with
ANRIL expression, but not with CDKN2A or CDKN2B expression
[36]. Liu et al reported that a different CAD risk allele rs10757278-
G was associated with reduced expression levels of CDKN2A,
CDKN2B, and ANRIL, but in the same study found no correlation
for five other SNPs tested, including two additional SNPs
associated with CAD (rs518394 and rs564398). They also found
no association for two SNPs associated with diabetes (rs10811661
and rs564398), the frailty risk SNP rs2811712, and a melanoma
risk SNP (rs11515) [37]. We demonstrated that CAD risk SNPs
rs1333045-C and rs10757278-G both correlate with ANRIL
underexpression, but found no correlation of these SNPs with
CDKN2A or CDKN2B expression. However, we identified highly
significant influences on expression associated with other SNPs for
which Liu et al found no association (rs10811661 with CDKN2A
and ANRIL; rs564398 with ANRIL; rs2811712 with CDKN2B;
rs11515 with CDKN2A and CDKN2B). These findings are likely to
reflect the greater power of our analysis for detection of cis-acting
effects due to the larger sample size and increased sensitivity of our
aeQTL mapping approach.
The finding that disease associated SNPs are all associated with
ANRIL expression suggests that ANRIL plays a role in influencing
disease susceptibility. Although little is known about the targets of
ANRIL, its effects may be mediated through antisense transcription
regulation of CDKN2B in the tissues critical for the pathogenesis of
the different diseases. The observation that the effects of sequence
variants acting in cis were stronger for ANRIL than for CDKN2B
may reflect selection pressure against variants that have substantial
direct effects on the expression of critical genes. CDKN2A, ARF and
CDKN2B are cell cycle regulators and are plausible candidates for
involvement in the pathogenesis of the diseases for which we found
SNP associations with ANRIL. Mutations involving these genes are
well documented in glioma [63,64] and melanoma [49,65,66].
Overexpression of CDKN2A and CDKN2B in murine models is
associated with pancreatic islet hypoplasia and diabetes [67,68],
and there is also emerging evidence that vascular cell senescence
involving these pathways is involved in the pathogenesis of
atherosclerosis [69,70].
Our data show that multiple independent sites in the
chromosome 9p21 region influence CDKN2A, CDKN2B and
ANRIL expression. SNPs associated with disease in GWA studies
are all associated with ANRIL expression, indicating that
modulation of ANRIL expression mediates susceptibility to a
variety of conditions.
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Participants
Peripheral blood for DNA and RNA analysis was collected from
anonymous adult volunteers in two cohorts: 310 SA blood donors
and 177 British Caucasians from north-east England. The self-
reported ethnicity of the SA cohort was: 200 Cape mixed-ancestry;
67 African black; 19 Indian; 10 white; 4 other/unknown. 42%
were male, with median age 20 years (range 17–60, lower quartile
19, upper quartile 23). In the Caucasian cohort, 50% were male,
with median age 63 years (range 25–101, lower quartile 51, upper
quartile 69).
Ethics statement
The study complies with the principles of the Declaration of
Helsinki. Informed consent was obtained from all participants and
the study was approved by the Newcastle and North Tyneside
Local Research Ethics Committee and the University of Cape
Town Faculty of Health Sciences Research Ethics Committee.
DNA and RNA extraction and cDNA synthesis
For the South African samples DNA was extracted using a
phenol/chloroform method from 4ml of peripheral blood in
EDTA collected at the time of the RNA sample. For the British
samples, DNA was obtained from the RNA solution prior to
DNase treatment.
RNA was extracted from 2.5ml of peripheral blood collected
using the PAXgene system (Qiagen) following the manufacturer’s
protocol and was DNase treated using RQ1 RNase-Free DNase
(Promega). For AEI measurements, approximately 2mg of total
RNA was reverse transcribed and eluted in 20ml, using
SuperScript VILO cDNA Synthesis Kit (Invitrogen) for the SA
samples and SuperScript III First-Strand Synthesis System for RT-
PCR (Invitrogen) for the British samples. For real-time PCR
measurements, 500ng of total RNA was reverse transcribed using
High Capacity RNA-to-cDNA Master Mix (Applied Biosystems)
and eluted in 20ml.
Selection of transcribed SNPs for allelic expression
analysis
Using the NCBI Entrez Gene database (http://www.ncbi.nlm.
nih.gov/, 28/01/08), transcribed SNPs with expected heterozy-
gosity .0.2 in the HapMap CEU population were selected as
suitable candidates for assessment of allelic expression. Tran-
scribed polymorphisms in ANRIL, which was not annotated in the
databases at the time of the design, were identified by comparing
the reported mRNA sequence [49] with NCBI dbSNP. Tran-
scribed SNPs selected using these criteria were: rs3088440 and
rs11515 in exon 3 of CDKN2A; rs3217992 and rs1063192 in exon
2o fCDKN2B; rs10965215 and rs564398 in exon 2 of ANRIL. The
two CDKN2A SNPs are also present in ARF, allowing the
assessment of cis-acting influences on both of these transcripts.
Another SNP rs10738605 in exon 3 of ANRIL also satisfied these
criteria but was subsequently excluded due to poor performance of
the assay.
Selection of mapping SNPs
SNPs previously reported to be associated with disease
phenotypes were selected for mapping effects on expression
[6,8,9,13–19,43,45–48,71–74]. Additional tag SNPs required to
capture common variation in a core region of interest
(Chr9:21958155–22115505) based on HapMap CEU data were
also selected using HaploView 4.0 Tagger software using the
following parameters: minimum minor allele frequency 0.01,
pairwise tagging, r
2 threshold .0.8. SNPs within other function-
ally important elements such as CDKN2A and CDKN2B promoters
[26,29,30,75] or a putative ANRIL promoter region (which we
arbitrarily defined as 1kb up and downstream of the transcription
start site) were selected if they were reported more than once in
NCBI dbSNP, had expected heterozygosity .5%, and were
associated with alteration of transcription factor binding sites
(using PROMO v.3.0.2) [76,77]. Details of included SNPs are
shown in Table S1.
Genotyping
Multiplex SNP genotyping was performed by primer extension
and MALDI-TOF mass spectrometry using iPLEX Gold
technology from Sequenom (Sequenom Inc, San Diego, USA).
SNP assays were designed using Sequenom’s RealSNP (www.
RealSNP.com) and MassARRAY Assay Design v3.0 Software
(multiplex details and primer sequences available in Table S4).
PCR was performed using 20ng of DNA in a 10ml reaction volume
for 35 cycles using standard iPLEX methodology. Spectra were
analysed using MassARRAY Typer v3.4 Software (Sequenom).
Spectra and plots were manually reviewed and auto-calls were
adjusted if required. Positive and negative controls were included.
Individual samples with low genotype call rates (,80%) and SNP
assays with poor quality spectra/cluster plots were excluded.
Correspondence to Hardy-Weinberg proportions was checked for
each SNP.
Measurement of allelic expression ratios
PCR primers for the selected transcribed SNPs were designed
using Primer3 (v.0.4.0) software [78]. CDKN2A primers span exons
3–4 and include both transcribed SNPs (rs3088440 and rs11515)
in the same amplicon. ANRIL primers span exons 1–2 and include
both transcribed SNPs (rs10965215 and rs564398) in the same
amplicon. For CDKN2B, separate primer pairs for transcribed
SNPs rs1063192 and rs3217992 were designed entirely within
exon 2 (due to the distance of transcribed SNPs from the exon
boundary).
Quantification of the allelic expression ratio was performed by
primer extension and MALDI-TOF mass spectrometry using
iPLEX Gold with similar parameters to the genotyping assay.
Spectra were analysed using MassARRAY Typer v3.4 Software
(Sequenom) and allelic ratios were estimated as the ratios of the
area under the peak representing allele 1 to that representing allele
2. Measurements were performed in four replicates using 50ng of
cDNA template. Results from amplification of genomic DNA were
used as an equimolar reference to normalise the cDNA values.
Genomic normalisation reactions for CDKN2B used the same PCR
primers as used for cDNA, but for CDKN2A and ANRIL (where
primers were cDNA-specific) separate assays designed to be as
close as possible in size and location to the cDNA primers were
used. Primer sequences are shown in Table S3. For some assays
the allelic ratios measured in gDNA ratios did deviate from a 1:1
ratio, as shown in Table S4, confirming that allelic ratios in cDNA
required correction for assay bias. However, as expected the
gDNA ratios for each assay were relatively homogeneous with little
inter-individual variability compared to cDNA ratios (Figure S1
and Figure S2). We compared the results of expression mapping
using two different normalisation strategies in the SA cohort:
normalising to a mean population normalisation factor versus
normalising each individual’s cDNA to their own gDNA ratio.
There was no difference in the results obtained using these two
normalisation strategies, as shown in Figure S8. The mean gDNA
ratios for each assay were the same in the SA cohort and a sample
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sample t-test), and we therefore used the mean gDNA ratios for
normalisation of all samples.
The appropriateness of genomic normalisation ratios and
linearity of the AER response were checked by mixing PCR
products from individuals homozygous for the minor and major
alleles in varying ratios (8:1, 4:1, 1:1, 1:4, 1:8) and using these as
template for the allelic expression assays. These experiments
confirmed that allelic expression showed a linear response and that
normalisation ratios obtained using allelic expression assays on a
1:1 mixture of alleles for each SNP correspond to normalisation
ratios obtained from genomic DNA (Table S4 and Figure S9).
Allelic expression ratios for the two transcribed markers in each
gene were highly correlated (CDKN2A r=0.68, p=1.7610
23;
CDKN2B r=0.80, p=1.7610
212; ANRIL r=0.90, p=1.0610
226;
all genes combined r=0.96, p=3610
261) as shown in Figure S5;
we therefore used a novel approach of combining allelic ratios
from the two transcribed markers in each gene to increase the
number of informative heterozygotes.
Relative quantification of total gene expression using
real-time PCR
Real-time PCR reactions were performed using TaqMan gene
expression gene expression probes and reagents (Applied Biosys-
tems) and run on a 7900HT Real-Time PCR System (Applied
Biosystems). Commercially available FAM-labelled TaqMan
assays were used for CDKN2A exons 2–3 (Hs00923894_m1) and
ANRIL exons 1–2 (Hs01390879_m1). A custom FAM-labelled
assay was used for exon 2 of CDKN2B. Commercially available
VIC-labelled TaqMan assays were used for three reference genes
shown to be suitable for normalisation of expression in peripheral
blood [79,80]: B2M (4326319E), GAPD (4326317E), and HPRT1
(4326321E). TaqMan assays are validated by the manufacturer to
have close to 100% amplification efficiency and assays were
selected to quantify the same transcripts as the allelic expression
assays. PCR was performed according to the manufacturer’s
protocol using four replicates, 25ng cDNA template per reaction,
and the following multiplex combinations: CDKN2A/B2M,
CDKN2B/GAPD, and ANRIL/HPRT1.
Relative total expression was analysed using the comparative
cycle threshold (Ct) method. Ct values for each target gene were
normalised to the mean Ct value of the three reference genes [79].
Standard errors and variances of measurements for allelic and
total expression analyses in the SA population are shown in Table
S5.
Statistical analyses
The association between total expression, as measured by real
time PCR, and each of the SNPs was assessed using linear
regression of the log transformed normalized expression values on
the genotype assuming no dominance or interactions between the
effects of different SNPs. The effect of including age, sex, and
ethnicity as covariates, as well as excluding outlying individuals as
determined by visual inspection (highlighted in Figure S4) were
investigated. Self reported ethnicity was included as a categorical
variable (categorised as ‘‘Cape mixed-ancestry’’, ‘‘black African’’,
‘‘white’’, ‘‘Indian’’, and ‘‘other’’). These corrections made no
significant difference to the results of eQTL mapping (Figure S6).
All analyses were performed using the corrected data. Plots
illustrating the associations between genotype and total expression
for selected SNPs are shown in Figure S10.
We analysed allelic expression ratios using an extension of the
approach we published previously [52]. We restrict ourselves to
biallelic markers, and code one arbitrarily chosen allele as 0 and
the other as 1. We designate with g the phase-known and with T
the phase-unknown genotype of an individual. The latter can be
ascertained through genotyping. We assume that the amount of
mRNA originating from a single allele follows a lognormal
distribution where the variance does not vary between different
alleles. The log of the ratio between the expression levels of both
alleles, I, can therefore be assumed to be normally distributed.
For an individual that is heterozygous for m transcribed
polymorphisms, m ratios can be determined. We designate the
vector of the logarithms of these ratios as I~ I1,:::,Im    0
. Under
the assumptions above, the components of I are normally
distributed with Ik*N mk g ðÞ ,sk ðÞ where the means mk g ðÞ depend
on the genotype g but the variance sk is genotype independent but
may depend on the site used to measure the allelic expression
ratio. We model the expected value as a linear combination of the
influences of the typed polymorphisms:
mk g ðÞ ~
X n
i~1
aihik g ðÞ ,
where ai represents the effect of the i
th cis acting markers; and hik
characterizes the phase between transcribed and putative cis acting
markers:
hik g ðÞ ~
1 if the genotype at markers i and k is 11=00
{1i f i t i s 1 0 =01
0 otherwise
8
> <
> :
In order to assess the association between a specific SNP and
allelic expression, let us consider a set of L individuals. For an
individual l (l~1,:::,L) we can measure the unphased genotype Tl
and a vector representing the log of the allelic expression ratios Il.
Up to a multiplicative constant the likelihood of observing a
certain pattern of imbalance in this set of individuals given their
genotyping results is:
L~P
l
fI lDTl ðÞ
with
fI lDTl ðÞ ~
X
g
fI lDg ðÞ Pg DTl ðÞ
where Pg DTl ðÞ designates the probability of the phased genotypes g
given the genotyping results Tl and fI lDg ðÞ describes the density of
the distribution of Il given the genotype g. Pg DT ðÞ was estimated
using the hap procedure from the R-package gap (as deposited in
the CRAN archive http://cran.r-project.org/) to phase the
genotypes of the two populations separately.
We assume that the allelic expression ratios measured at
different sites are conditionally independent given the genotype.
Therefore:
fI lDg ðÞ ~P
k
fI k
l Dg
  
where fI k
l Dg
  
~fI k
l ;mk g ðÞ ,sk
  
and fI k
l ;mk g ðÞ ,sk
  
denotes the
density of a normal distribution with the individual expression
ratio Ik
l as variate, a genotype dependent mean mk g ðÞand a
variance s2
k. Therefore L depends on ai (i=1,…,n) and sk
(k=1,…,m), and maximisation of this likelihood allows assessment
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effects of other markers by comparing nested models using
likelihood ratio tests.
For both total and allelic expression multiple testing was taken
into account by calculating the family wise error rate using a
Bonferroni correction for the 56 SNPs tested. Associations with
family wise error rate below a threshold of 0.05 (corresponding to
a nominal P-value of 8.9610
24, 2log10P of 3.05, and
2log10FWER of 1.3) were called significant.
From our allelic and total expression data we also estimated the
proportion of total expression variance that is due to cis-acting
effects. This assumes that cis and trans-acting factors act in an
additive manner, do not interact, are independent and that there is
random mating, no segregation distortion, and the locus is not
subject to imprinting. Given these assumptions, we estimate
the variance due to cis acting effects, Vc ðÞ ,a s^ V Vc ðÞ ~
1
2 n{1 ðÞ
X n
i~1
e2
Ti
1{ri
1zri
   2
, where ri is the allelic expression ratio
for individual i, and the proportion of the total variance due to
cis acting effects can be estimated as
2^ V Vc ðÞ
^ V Ve T ðÞ
, where ^ V Ve T ðÞ is
the estimated total variance, i.e. ^ V Ve T ðÞ ~
1
n{1
X n
i~1
eTi{  e eT ðÞ
2
with   e eT~
1
n
X n
i~1
eTi and eTi represent the total expression level for
individual i as determined by real time PCR.
Supporting Information
Figure S1 Allelic expression ratios at transcribed SNPs in the SA
cohort. Y-axes show AER for the following transcribed SNPs: (A)
CDKN2A rs11515; (B) CDKN2A rs3088440; (C) CDKN2B
rs3217992; (D) CDKN2B rs1063192; (E) ANRIL rs564398; (F)
ANRIL rs10965215. Each point represents an individual, with
standard error bars shown. Black circles represent cDNA
measurements and blue circles genomic DNA measurements.
Found at: doi:10.1371/journal.pgen.1000899.s001 (0.26 MB
DOC)
Figure S2 Allelic expression ratios at transcribed SNPs in the
Caucasian cohort. Y-axes shows AER for the following tran-
scribed SNPs: (A) CDKN2A rs11515; (B) CDKN2A rs3088440;
(C) CDKN2B rs3217992; (D) CDKN2B rs1063192; (E) ANRIL
rs564398; (F) ANRIL rs10965215. Each point represents an
individual, with standard error bars shown. Black circles represent
cDNA measurements and blue circles represent genomic DNA
measurements.
Found at: doi:10.1371/journal.pgen.1000899.s002 (0.21 MB
DOC)
Figure S3 Total expression values in the SA cohort. Y-axes
show normalised total expression Ct values relative to reference
genes for: (A) CDKN2A; (B) CDKN2B; (C) ANRIL. Each point
represents an individual, with standard error bars shown.
Found at: doi:10.1371/journal.pgen.1000899.s003 (0.19 MB
DOC)
Figure S4 Correlations between total expression levels of
CDKN2A, CDKN2B and ANRIL. Scatter plots show correlations
between total expression levels for: (A) CDKN2A and CDKN2B; (B)
CDKN2A and ANRIL; (C) CDKN2B and ANRIL. Expression values
on the X- and Y-axes are shown as delta Ct values for the target
gene relative to the three internal control genes. Circles represent
individual samples and the crosses represent three outliers
excluded from correlation analyses. Linear regression lines are
shown as solid lines, with dotted lines indicating the 95%
confidence intervals. Pearson correlation coefficient (r) and the
P-value for each association are shown in the top left of each plot.
Found at: doi:10.1371/journal.pgen.1000899.s004 (0.12 MB
DOC)
Figure S5 Correlation between AER in individuals heterozy-
gous for both transcribed markers in a gene. The X- and Y-axes
show the allelic expression ratio (AER) at the two transcribed
SNPs in each gene. Each point represents an individual who is
heterozygous for both transcribed SNPs in that gene. Circles
represent CDKN2A, squares CDKN2B, and triangles ANRIL.
Found at: doi:10.1371/journal.pgen.1000899.s005 (0.03 MB
DOC)
Figure S6 Effect of adjustment for covariates and outliers on
total expression mapping. Scatter plots depict the estimates of
effect size (A) and significance of association (B) for each of the 56
SNPs obtained using unadjusted total expression values (X-axis)
versus values adjusted for covariates (age, sex, ethnicity) and with
outliers removed (Y-axis). Pearson correlation coefficient (r) and
the P-value for each association are shown in the top left of each
plot.
Found at: doi:10.1371/journal.pgen.1000899.s006 (0.05 MB
DOC)
Figure S7 Linkage disequilibrium in the SA and Caucasian
cohorts. Figures show linkage disequilibrium between the 56 SNPs
in each population: (A) D9 in Caucasian cohort; (B) D9 in SA
cohort; (C) r
2 in Caucasian cohort; (D) r
2 in SA cohort. Colouring
in (A) and (B) represents D9 values: D9=1, LOD,2 (blue); D9=1,
LOD.2 (red); D9,1, LOD.2 (shades of pink); D9,1, LOD,2
(white). Shading in (C) and (D) represents r
2 values: r
2=1 (black);
0,r
2,1 (shades of grey); r
2=0 (white).
Found at: doi:10.1371/journal.pgen.1000899.s007 (1.05 MB
DOC)
Figure S8 Effect of individual normalisation of allelic expression
ratios. Scatter plots compare the estimates of effect size (A) and
significance of association (B) for each of the 56 SNPs obtained
using allelic expression ratios normalised to a combined normal-
isation factor (X-axis) versus individual normalisation of each
cDNA ratio to the gDNA ratio from the same individual (Y-axis).
Pearson correlation coefficient (r) and the P-value for each
association are shown in the top left of each plot.
Found at: doi:10.1371/journal.pgen.1000899.s008 (0.05 MB
DOC)
Figure S9 Linear relationship between measured and expected
allelic expression ratios for alleles mixed in known ratios (8:1, 4:1,
1:1, 1:4, 1:8) at each transcribed SNP. (A) CDKN2A rs3088440. (B)
CDKN2A rs11515. (C) CDKN2B rs3217992. (D) CDKN2B
rs1063192. (E) ANRIL rs10965215. (F) ANRIL rs564398.
Found at: doi:10.1371/journal.pgen.1000899.s009 (0.05 MB
DOC)
Figure S10 Effect of genotype on total expression of ANRIL for
selected SNPs. Y-axis shows the normalised total expression value
for ANRIL. X-axis shows genotype for SNPs with cis-acting effects:
(A) rs564398; (B) rs10965215; (C) rs7865618. Linear regression
lines are shown as solid lines, with dotted lines indicating the 95%
confidence intervals.
Found at: doi:10.1371/journal.pgen.1000899.s010 (0.10 MB
DOC)
Table S1 Summary of included SNPs. F=SNP removed from
analysis in this cohort as genotype available for ,80% of
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frequency; HW=Hardy-Weinberg.
Found at: doi:10.1371/journal.pgen.1000899.s011 (0.20 MB
DOC)
Table S2 Effect size and significance of association for SNPs
associated with disease. Data shown are for aeQTL mapping in
the combined population. Effects are reported as fold changes in
expression for individuals who are homozygous for the minor
allele relative to individuals who are homozygous for the major
allele (calculated from allelic expression data using two transcribed
SNPs per gene). Association for each SNP is presented as the
2log10 P-value and the 2log10 of the family wise error rate
(FWER) using a Bonferroni correction for the 56 SNPs tested.
Associations that were significant using a FWER threshold of 0.05
(corresponding to 2log10P of 3.05, or 2log10FWER of 1.3) were
regarded as significant.
Found at: doi:10.1371/journal.pgen.1000899.s012 (0.20 MB
DOC)
Table S3 Primer sequences.
Found at: doi:10.1371/journal.pgen.1000899.s013 (0.03 MB
XLS)
Table S4 Comparison of allelic expression normalisation ratios
obtained from genomic DNA and experimental equimolar
mixtures.
Found at: doi:10.1371/journal.pgen.1000899.s014 (0.03 MB
DOC)
Table S5 Comparison of variances between total expression and
allelic expression measurements in the SA cohort.
Found at: doi:10.1371/journal.pgen.1000899.s015 (0.03 MB
DOC)
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